|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHST2 |
Gene summary for CHST2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHST2 | Gene ID | 9435 |
| Gene name | carbohydrate sulfotransferase 2 | |
| Gene Alias | C6ST | |
| Cytomap | 3q24 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q9Y4C5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9435 | CHST2 | P9T-E | Human | Esophagus | ESCC | 6.79e-08 | 3.24e-01 | 0.1131 |
| 9435 | CHST2 | P10T-E | Human | Esophagus | ESCC | 2.26e-21 | 4.60e-01 | 0.116 |
| 9435 | CHST2 | P22T-E | Human | Esophagus | ESCC | 2.87e-07 | 2.29e-01 | 0.1236 |
| 9435 | CHST2 | P28T-E | Human | Esophagus | ESCC | 9.21e-24 | 5.27e-01 | 0.1149 |
| 9435 | CHST2 | P30T-E | Human | Esophagus | ESCC | 4.08e-11 | 5.80e-01 | 0.137 |
| 9435 | CHST2 | P31T-E | Human | Esophagus | ESCC | 1.01e-03 | 9.49e-02 | 0.1251 |
| 9435 | CHST2 | P32T-E | Human | Esophagus | ESCC | 3.16e-03 | 6.32e-02 | 0.1666 |
| 9435 | CHST2 | P36T-E | Human | Esophagus | ESCC | 9.47e-05 | 8.76e-01 | 0.1187 |
| 9435 | CHST2 | P52T-E | Human | Esophagus | ESCC | 2.59e-03 | 1.62e-01 | 0.1555 |
| 9435 | CHST2 | P62T-E | Human | Esophagus | ESCC | 5.07e-05 | 2.01e-01 | 0.1302 |
| 9435 | CHST2 | P91T-E | Human | Esophagus | ESCC | 1.18e-04 | 5.30e-01 | 0.1828 |
| 9435 | CHST2 | P107T-E | Human | Esophagus | ESCC | 3.43e-02 | 1.97e-01 | 0.171 |
| 9435 | CHST2 | C04 | Human | Oral cavity | OSCC | 5.43e-23 | 9.84e-01 | 0.2633 |
| 9435 | CHST2 | C21 | Human | Oral cavity | OSCC | 3.38e-09 | 3.50e-01 | 0.2678 |
| 9435 | CHST2 | C30 | Human | Oral cavity | OSCC | 1.66e-10 | 5.78e-01 | 0.3055 |
| 9435 | CHST2 | C38 | Human | Oral cavity | OSCC | 1.21e-09 | 1.26e+00 | 0.172 |
| 9435 | CHST2 | C43 | Human | Oral cavity | OSCC | 5.37e-20 | 4.22e-01 | 0.1704 |
| 9435 | CHST2 | C51 | Human | Oral cavity | OSCC | 2.00e-16 | 8.23e-01 | 0.2674 |
| 9435 | CHST2 | C06 | Human | Oral cavity | OSCC | 7.70e-15 | 2.06e+00 | 0.2699 |
| 9435 | CHST2 | C07 | Human | Oral cavity | OSCC | 2.05e-02 | 8.86e-01 | 0.2491 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00442725 | Esophagus | ESCC | sulfur compound biosynthetic process | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
| GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
| GO:002240919 | Esophagus | ESCC | positive regulation of cell-cell adhesion | 155/8552 | 284/18723 | 1.50e-03 | 7.06e-03 | 155 |
| GO:000268515 | Esophagus | ESCC | regulation of leukocyte migration | 114/8552 | 210/18723 | 7.26e-03 | 2.63e-02 | 114 |
| GO:190303916 | Esophagus | ESCC | positive regulation of leukocyte cell-cell adhesion | 128/8552 | 239/18723 | 8.40e-03 | 2.96e-02 | 128 |
| GO:0006024 | Esophagus | ESCC | glycosaminoglycan biosynthetic process | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
| GO:0006023 | Esophagus | ESCC | aminoglycan biosynthetic process | 47/8552 | 79/18723 | 9.29e-03 | 3.23e-02 | 47 |
| GO:000715918 | Esophagus | ESCC | leukocyte cell-cell adhesion | 192/8552 | 371/18723 | 1.03e-02 | 3.51e-02 | 192 |
| GO:190303717 | Esophagus | ESCC | regulation of leukocyte cell-cell adhesion | 174/8552 | 336/18723 | 1.36e-02 | 4.43e-02 | 174 |
| GO:004578520 | Oral cavity | OSCC | positive regulation of cell adhesion | 225/7305 | 437/18723 | 6.06e-08 | 1.09e-06 | 225 |
| GO:002240718 | Oral cavity | OSCC | regulation of cell-cell adhesion | 218/7305 | 448/18723 | 1.71e-05 | 1.68e-04 | 218 |
| GO:00442724 | Oral cavity | OSCC | sulfur compound biosynthetic process | 82/7305 | 148/18723 | 3.71e-05 | 3.31e-04 | 82 |
| GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
| GO:000268510 | Oral cavity | OSCC | regulation of leukocyte migration | 108/7305 | 210/18723 | 1.63e-04 | 1.13e-03 | 108 |
| GO:000715916 | Oral cavity | OSCC | leukocyte cell-cell adhesion | 178/7305 | 371/18723 | 2.44e-04 | 1.57e-03 | 178 |
| GO:190303715 | Oral cavity | OSCC | regulation of leukocyte cell-cell adhesion | 162/7305 | 336/18723 | 3.39e-04 | 2.08e-03 | 162 |
| GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
| GO:002240917 | Oral cavity | OSCC | positive regulation of cell-cell adhesion | 136/7305 | 284/18723 | 1.35e-03 | 6.62e-03 | 136 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHST2 | SNV | Missense_Mutation | rs868587203 | c.1094N>A | p.Arg365His | p.R365H | Q9Y4C5 | protein_coding | tolerated(0.05) | probably_damaging(0.973) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
| CHST2 | SNV | Missense_Mutation | novel | c.485A>T | p.Asp162Val | p.D162V | Q9Y4C5 | protein_coding | tolerated(0.23) | benign(0) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| CHST2 | SNV | Missense_Mutation | novel | c.486C>A | p.Asp162Glu | p.D162E | Q9Y4C5 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| CHST2 | SNV | Missense_Mutation | novel | c.578N>C | p.Leu193Pro | p.L193P | Q9Y4C5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A4SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CHST2 | SNV | Missense_Mutation | c.767A>G | p.Lys256Arg | p.K256R | Q9Y4C5 | protein_coding | tolerated(0.69) | probably_damaging(0.949) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | |
| CHST2 | SNV | Missense_Mutation | novel | c.1292N>C | p.Asp431Ala | p.D431A | Q9Y4C5 | protein_coding | tolerated(0.2) | benign(0.138) | TCGA-BH-A0BS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
| CHST2 | SNV | Missense_Mutation | rs373790739 | c.1240N>A | p.Asp414Asn | p.D414N | Q9Y4C5 | protein_coding | tolerated(0.29) | possibly_damaging(0.562) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| CHST2 | SNV | Missense_Mutation | novel | c.817G>A | p.Gly273Arg | p.G273R | Q9Y4C5 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CHST2 | SNV | Missense_Mutation | c.1456N>A | p.Ala486Thr | p.A486T | Q9Y4C5 | protein_coding | tolerated(0.51) | possibly_damaging(0.574) | TCGA-C5-A2LV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHST2 | SNV | Missense_Mutation | c.1364N>T | p.Ala455Val | p.A455V | Q9Y4C5 | protein_coding | tolerated(0.94) | benign(0.125) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |